A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

NCT06004336 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

144

Enrollment

OTHER

Sponsor class

Conditions

Oligometastatic Renal Cell Carcinoma

Interventions

DRUG: Pembrolizumab
RADIATION: Radiation therapy

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]